Kornimate/medical-research-clean huggingface dataset:
effect of whole body vibration on functional capacity and respiratory functions in stroke individuals

Conditions: Stroke; Respiratory Function Impaired

Summary: while there is only one study examining the effect of wbv on oxygen consumption and cardiovascular responses in individuals with stroke, no study has been found on the effect of wbv on respiratory capacity and flow volumes and changes in functional capacity due to effort. in this study, it was aimed to investigate whether the wbv treatment protocol determined has an effect on functional capacity and respiratory functions in individuals with stroke.


Eligibility criteria:
inclusion criteria: * having first hemiplegic stroke history at least for 3 months, being clinically stable could stand for at least 1 minute, could walk independently with or without a walking aids. exclusion criteria: * having any neurological, psychiatric, orthopedic and unstable cardiovascular and pulmonary conditions other than stroke.

Keywords: stroke bobath approach whole body vibration functional capacity respiratory function
ctdna as a biomarker for treatment in advanced nsclc

Conditions: Non-small Cell Lung Cancer

Summary: the dynamic monitoring of circulating tumor dna aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or metastatic non-small cell lung cancer.

for patients with locally advanced unresectable or metastatic non-small cell lung cancers, 4-6 cycles of chemotherapy plus immunotherapy with immune maintenance therapy is currently the standard treatment. short-course chemotherapy (2 cycles) combined with immunotherapy has been proved effective in some patients. recently, circulating tumor dna (ctdna) has been detected in the cell-free component of peripheral blood samples in advanced non-small cell lung cancers and many other solid tumors. to identify the patients who can benefit from the short-course chemotherapy (2 cycles) combined with immunotherapy, dynamic monitoring of ctdna in both 4-6 cycles and 2 cycles chemotherapy patients could be a promising alternative test.

Eligibility criteria:
inclusion criteria: * (1)histologically confirmed non-small cell lung cancer; (2)locally advanced unresectable or metastatic disease; (3)male or female aged over 18 years and under 80 years; (4)subjects must not have received any immunotherapy for advanced lung cancer, and have an estimated life expectancy of more than 12 weeks (5)eastern cooperative oncology group (ecog) score as 0 \~ 1; (6)no egfr mutation, alk or ros1 rearrangement; (7)adequate tumor tissue for pd-l1 testing; (8)with at least one measurable lesion confirmed by the investigator according to response evaluation criteria in solid tumors (recist) (version 1.1)； (9)the subjects must sign the informed consent, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study. exclusion criteria: * (1)serious immune-related adverse events occurred; (2)participation in other clinical study; (3)with the history of autoimmune disease or immunodeficiency disease; (4)history of another primary malignancy within 5 years; (5)without complete clinical information; (6)pregnant or lactating women; (7)other conditions in which the investigator believes that the patient should not participate in this trial.

Keywords: circulating tumor dna immunotherapy chemotherapy (2/4~6 cycles)
phase i study of mitoxantrone hydrochloride liposome injection

Conditions: Malignant Lymphoma

Summary: the purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of mitoxantrone hydrochloride liposome injection.

the trial of the dose escalation method is from 18mg/m2 until the maximum tolerated dose and every 3 patient is a dose group.

Eligibility criteria:
inclusion criteria: * patients must compliance with the requirements and restrictions listed in the consent form * patients with pathology and / or cytologically proven malignant lymphoma * patients must be 18-70 years old ,both male and female * failure of standard chemotherapy * patients have no better choice and may be benefit from the use of anthracyclines * patients with eastern cooperative oncology group (ecog)performance status of 0-2 * objective tumor from the last chemotherapy, biological therapy or other experimental interval treatment least 4 weeks * expected survival time ≥ 3 months * patients agreed to take effective contraceptive measures during the trial * blood routine, liver and kidney function, cardiac function examination in accordance with the following requirements. exclusion criteria: * pregnancy and breast-feeding women * multiple sclerosis * patients that have histories of ischemic heart disease and heart congestive,arrhythmia that need to be a treatment and significant valvular disease * patients with heart disease induced by anthracycline * patients requiring other antineoplastic treatment * patients with temperature above 38 degrees or active infection that may effects in clinical tests * patients are allergic to anthracycline and liposomal drugs * patients are allergic to eggs,egg products,soybean and soybean products * patients with uncontrolled primary or metastatic brain tumorsmultiple sclerosis * patients that have histories of ischemic heart disease and heart congestive,arrhythmia that need to be a treatment and significant valvular disease * patients with heart disease induced by anthracycline * patients requiring other antineoplastic treatment * patients with temperature above 38 degrees or active infection that may effects in clinical tests * patients are allergic to anthracycline and liposomal drugs * patients are allergic to eggs,egg products,soybean and soybean products * patients with uncontrolled primary or metastatic brain tumors * total amount of doxorubicin(or pirarubicin)≥360mg/m2,epirubicin ≥600mg/m2

Keywords: safety;malignant lymphoma;
safety and effectiveness of apixaban in very elderly patients with non-valvular atrial fibrillation (nvaf) compared to warfarin using administrative claims data

Conditions: Non-valvular Atrial Fibrillation

Summary: the objective of this study is to investigate safety and effectiveness of apixaban compared to warfarin in very elderly patients with non-valvular atrial fibrillation (nvaf). in addition to the absolute age, effects on higher age-related risk factors on relative risk of apixaban to warfarin is also investigated through subgroup analyses.

this is a retrospective non-intervention observational study to evaluate the difference in safety and effectiveness between apixaban and warfarin using a database provided by medical data vision co. ltd. (mdv co. ltd.). eligible patients will be extracted from the database and allocated to the pre-defined cohorts based on the actual age, age of nvaf diagnosis and types of anticoagulant therapy. patient characteristics will be balanced by an inverse probability of treatment weighting (iptw) method, and risk of stroke/se (primary effectiveness endpoint) and major bleeding (primary safety endpoint) will be compared.

Eligibility criteria:
inclusion criteria: * patients must meet all the following inclusion criteria to be eligible for inclusion in the study. 1. diagnosed with atrial fibrillation (af) anytime in the baseline period or on the index date, also have definitive diagnosis of af anytime in the baseline period, on the index date, or post-index period. 2. prescribed apixaban or warfarin on or after the day of af diagnosis. the first observed prescription will be used to identify the patient's index date and treatment cohort 3. no use of the any oral anticoagulants (oac)s during the baseline period (the 180 days before the index date) 4. age of 18 years or older on the index date. 5. index date is at age 80 or older exclusion criteria: * patients meeting any of the following criteria will not be included in the study: 1. having a diagnosis of valvular atrial fibrillation, post-operative atrial fibrillation, rheumatic atrial fibrillation or mechanical-valvular atrial fibrillation during the baseline and post-index period 2. having a cardiac surgery procedure record during the baseline period 3. having a joint replacement procedure record during the baseline period 4. having a procedure of prosthetic heart valve during the baseline period 5. having a diagnosis of venous thromboembolism during the baseline period 6. female patients with pregnancy during the follow-up period 7. patients prescribed "off-label" doses of oacs (per japanese package insert of each oac) or patients treated with oac but in "off-label" or "contraindicated" manners.

Keywords: stroke apixaban warfarin
immunesense covid-19 variant study

Conditions: Covid19

Summary: this study will assess the clinical performance of the t-detect™ covid test to identify an immune response to sars-cov-2 infection in the setting of multiple circulating variants of the sars-cov-2 virus. performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of sars-cov-2 and their prevalence, which changes over time.


Eligibility criteria:
general inclusion criteria inclusion criteria: participants must satisfy the following criteria to be enrolled in the study: i. individuals who have tested positive for sars-cov-2 via eua rt-pcr testing. ii. male and female participants of any race and ethnicity between 18 to 89 years of age (inclusive) at the time of enrollment in the study. iii. must be able to communicate with the investigator, understand, and comply with the requirements of the study. iv. must be able to provide estimated date of symptom onset. v. must be available for specimen collection greater than 14 days (i.e., 15 days inclusive onward) and less than 107 days (i.e., 106 days inclusive or less) after first exhibiting symptoms of confirmed sars-cov-2 infection. exclusion criteria: the presence of any of the following will exclude a participant from enrollment: * individuals who did not test positive for sars-cov-2 on eua rt-pcr. * protected populations including pregnant women, prisoners, mentally disabled persons, and wards-of-the state. * any significant condition, laboratory abnormality, or psychiatric illness that would prevent the participant from safely participating in the study. * exposure to a sars-cov-2 investigational drug (new chemical entity) within 60 days prior to enrollment at the discretion of the sponsor. * receipt of immunosuppressive medications, such as, but not limited to, recent moderate- or high-dose systemic steroids or immunomodulators within 1 month prior to enrollment at the discretion of the sponsor. * treatment with immunosuppressants/ immunomodulators that do not impact t cells or b cells may be allowed at the discretion of the sponsor. * steroid formulations including low-dose oral steroids (≤ 10 mg prednisone equivalents per day), inhaled steroids, or topical steroids are not considered exclusionary. doses \>10 and \<20 mg prednisone equivalents per day, must receive sponsor approval.

Keywords: variant
design of a standardized patient: mentoring program for kidney transplant patients

Conditions: Kidney Transplant; Complications

Summary: there is an increasing number in patient's undergoing kidney transplantation in the united states. furthermore, kidney recipients have high occurrence of 30-day readmissions that leads to high hospital costs and decreased quality of life for transplant recipients. a previous research finds that high levels of post-transplant anxiety is correlated with increased likelihood of 30-day readmissions. the goal of this study is to design and implementat a randomized control trial (rct) using a standardized post-transplant mentoring program in order to reduce 30-day readmission and post-transplant anxiety among recipients.

in this research, the investigators will seek to examine the efficacy of using former patients as mentors to newly transplanted patients and its relationship with patient anxiety following discharge as well as the prevention of 30-day readmissions for kidney transplant recipients. the primary hypothesis is that the treatment group of patients who undergo a targeted mentorship program will be better compliant with the discharge instructions and will perform better when compared to the control group who undergoes current routine post-transplantation care. evidence from this experiment can help advance our understanding of patient-engagement in the continuity of care delivery, decrease patient readmission rates, and improve overall cost utilization. methods: the investigators will conduct a single institution randomized control trial assigning patients getting discharged after a kidney transplant to a treatment group that involves a 30-day mentoring initiative by former transplant patients, and comparing the efficacy with a similar control group. the overall study period will be divided into the following sections, summarized in figure 1.

Eligibility criteria:
inclusion criteria: * any patient who received a kidney transplantation, deceased or living donor, during the study period. exclusion criteria: * anyone younger than 18 years old or older than 70 years old.
barriers and facilitators to mmr vaccination among healthcare workers

Conditions: Measles

Summary: measles is a highly contagious disease which can result in severe complications in some patients. healthcare workers have a higher risk of getting measles than the general population because of their increased risk of exposure from patients with measles attending hospitals. having had measles in the past or at least one dose of the measles, mumps and rubella (mmr) vaccine provides protection (immunity) against measles. uk government guidelines therefore recommend that healthcare workers and non-clinical staff with direct patient contact are fully vaccinated or have other evidence of immunity. yet, evidence from recent measles outbreaks suggests that some healthcare workers are not immune or do not know if they are immune, with implications for containment efforts, cost and transmission. the purpose of this study is to identify barriers and facilitators to uptake of the mmr vaccine among healthcare workers at king's college hospital nhs foundation trust (kch). kch healthcare workers will be eligible to take part in the study if they are aged 18 and over and have direct contact with patients. in addition, the research will focus on four subgroups of healthcare workers at kch: those who are not immune, those who have not completed the full vaccination schedule, those who don't know their immunity status, those received the vaccine only after joining kch. the latter may provide insights into facilitators to vaccine uptake. measles immunity forms part of the occupational health screening at kch. a series of semi structured interviews lasting approximately 1 hour will explore participants' experiences of the occupational health vaccine screening process and measles vaccine campaigns at kch; why they are unvaccinated/not fully vaccinated/do not know if they are immune/decided to be vaccinated after joining kch; and what measures or interventions may help healthcare workers when deciding whether to get the mmr vaccine.


Eligibility criteria:
inclusion criteria: * are aged 18 and over * currently work as a healthcare worker at the trust * have direct contact with patients * don't know if they have had measles and don't know if they have been vaccinated * or: have not had measles and have not received the mmr vaccine * or: have only received 1 dose of the mmr vaccine * or: received the mmr vaccine after joining the trust exclusion criteria: * are aged \<18 years old * work in a role at the trust that does not involve direct contact with patients (e.g., administrative or business staff) * are sure and/or have evidence that they have had measles in the past or both doses of the mmr vaccine before joining the trust * are not able to give informed consent
understanding the mechanisms of autism : an mri and social cognition study

Conditions: Autism Spectrum Disorder

Summary: the main goal of this study is to investigate anatomo-functional brain abnormalities associated with autism spectrum disorders using a multimodal brain imaging approach, as well as its links to social cognition difficulties measured using eye-tracking

autism spectrum disorders (asd) are neurodevelopmental disorders whose first manifestations appear early in childhood. even if asds present a wide heterogeneity in clinical manifestations, abnormalities in social behavior, characterized in particular by a lack of preference for social information, remain the core of difficulties characteristic of autism. brain imaging investigations have revealed anatomo-functional abnormalities in autism, particularly in social brain regions. in parallel, eye-tracking studies have provided objective measures of social perception abnormalities in autism. these results illustrate the relevance of these research strategies in the context of asd. acquiring objective data on social behavior and linking them with brain imaging data opens up new avenues for research into the evolution of social skills during child development, and the brain changes underlying this process. in this context, the main hypothesis of this study is that the investigation of the neural bases of autism spectrum disorders, using an approach combining multimodal brain imaging and the investigation of social behavior using eye-tracking, would make it possible not only to better describe abnormalities, but also to identify individual patterns at brain and behavioral level. this could help to better characterize asds with and without genetic abnormalities, an area which to date has received very little investigation. in addition, the objective measurements obtained with this approach would also enable the proposal of biomarkers, which would contribute not only to better monitoring of the disorder's evolution, but also to the evaluation of the effectiveness of new therapeutic interventions

Eligibility criteria:
inclusion criteria: for subjects diagnosed with asd or suspected of asd : * 3 months ≤ age \< 25 years ; * an mri required as part of the clinical procedures * written consent obtained from parents or legal guardians. * affiliated to social security for healthy control subjects over 3 years of age: * between 3 and 18 years of age * no known neurological or psychiatric pathology * written consent obtained from parents or legal guardian. * affiliated to social security for healthy control subjects under 5 years of age: * age between 3 months and 5 years * who have had an mri scan in the pediatric radiology department at necker hospital, which was found to be normal. * with no known neurological or psychiatric pathology * no opposition from legal representative exclusion criteria: * contraindication to mri (pacemaker, intracorporeal metallic body, claustrophobia). * impossibility for healthy volunteers to remain still during mri

Keywords: autism spectrum disorders multimodal brain imaging eye-tracking social perception genetics developmental trajectory
assessing a new tool to assess frailty in frail hospitalized elderly

Conditions: Frail Elderly Syndrome

Summary: the major purpose of this study is to establish the use of daily step counts as inexpensive, easy to measure marker for frailty and sarcopenia in an inpatient population of older adults.

the total time involved to complete study procedures will be between 2-3 hours at your enrollment and up to 10 minutes at your discharge. investigators will invite participants to enrol in this study at your admission and discharge days. firstly, investigators would like to collect some demographic data, including participants age and gender. then investigators will ask participants to check their blood pressure and heart rate, weight, height and body mass index. also investigators will collect participant's medication list and past medical history. then, investigators would like to ask participants to carry special device on their mid-thigh. it's called 'activpal' and a trained research assistant will fit it on participant's dominant leg. this device has ability to detect the joint angle of participant's thigh to capture lying, sitting, standing, and stepping activities. then investigators will proceed to ultrasound test. participants will be asked to lay down on the bed with their legs supported by a pillow. then a study physician will use ultrasound to measure participant's leg muscles. three measurements will be taken for each participant. after that participant will be asked to do a "grip test". participant will be asked to squeeze special device, called dynamometer, using your dominant hand. each participant will be asked to make three attempts with half a minute break between each measurement. participant will be asked to walk 10-15 meters in order to measure their gait speed. impedance measures of body composition will be performed using an automatic scale. at the end investigators will ask you to measure participant's body structure, using skinfold/caliper device. at participant discharge investigators will remove 'activpal' sensor from their leg that was fitted at enrollment.

Eligibility criteria:
inclusion criteria: * be 65 years of age or older * be admitted in ace unit exclusion criteria: * be less than 65 years of age * be nonambulatory * be diagnosed with end-stage organ failure (end-stage copd, renal failure requiring dialysis, end-stage heart failure)
a phase 2, multicenter, randomized, double-blind, vehicle controlled, parallel-group, clinical study in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: a phase 2, multicenter, randomized, double-blind, vehicle controlled, parallel-group, clinical study in the treatment of acne vulgaris

a phase 2, multicenter, randomized, double-blind, vehicle controlled, parallel-group, clinical study comparing the efficacy and safety of idp-126 gel in the treatment of acne vulgaris

Eligibility criteria:
inclusion criteria: 1. male or female at least 9 years of age and older. 2. written and verbal informed consent must be obtained. subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit). 3. subject must have an egss of 3 (moderate) or 4 (severe) at the baseline visit. 4. subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20, but no more than 100. 5. subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 30, but no more than 150. 6. subjects with 2 or fewer facial nodules exclusion criteria: 1. use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study. 2. any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema. 3. any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive. 4. subjects with a facial beard or mustache that could interfere with the study assessments. 5. subjects with more than 2 facial nodules. 6. evidence or history of cosmetic-related acne.